SUR1 R1420H变异对胰岛素分泌功能的影响:基于等基因iPSC来源胰岛的研究
研究利用CRISPR-Cas9构建SUR1 R1420RR、RH和HH三种基因型的等基因iPSC,并分化为未成熟和成熟胰岛,评估胰岛素分泌动态及基因表达。结果发现HH未成熟胰岛基础胰岛素分泌增加但成熟后丧失葡萄糖反应性;RH未成熟胰岛轻度高胰岛素血症,成熟后葡萄糖反应性降低,提示SUR1 R1420H为KATP通道功能丧失变异,可解释杂合子2型糖尿病风险增加。
要点
- SUR1 1420HH未成熟胰岛基础胰岛素分泌显著增加,成熟后无葡萄糖反应性。
- SUR1 1420RH未成熟胰岛轻度高胰岛素血症,成熟后葡萄糖反应性显著降低。
- 等基因iPSC平台可用于筛选改善杂合子葡萄糖反应性胰岛素分泌的药物。
核心结论
- SUR1 R1420H是KATP通道功能丧失变异,纯合子导致未成熟胰岛高胰岛素血症及成熟后葡萄糖反应性丧失,杂合子成熟后胰岛素分泌反应降低,可能解释2型糖尿病风险增加。
研究设计与样本
- 利用CRISPR-Cas9在两种美洲原住民iPSC系(IS1和IS2)中构建SUR1 1420RR、1420RH和1420HH等基因细胞,分化为未成熟和成熟胰岛用于胰岛素分泌评估和单细胞RNA测序。
主要发现
- 未成熟SUR1 1420HH胰岛基础胰岛素分泌较正常增加3.4倍(IS1,p<0.001)和4.2倍(IS2,p=0.001)。
- 未成熟SUR1 1420RH胰岛基础胰岛素分泌增加2.2倍(IS1)和2.3倍(IS2),但无统计学显著性。
- 成熟SUR1 1420HH胰岛无葡萄糖反应性;成熟SUR1 1420RH胰岛呈双相分泌但葡萄糖反应性显著低于正常(高糖刺激下胰岛素分泌AUC占总量百分比:正常1.04 vs 1420RH 0.56,p<0.001)。
- 二氮嗪降低未成熟1420RH和1420HH胰岛的高胰岛素血症;甲苯磺丁脲对成熟1420RH(13.2倍增加)和1420HH(1.9倍增加)的胰岛素分泌反应远低于正常(31.5倍增加)。
- SUR1 1420RH胰岛对葡萄糖激酶激活剂多格列艾汀有反应,改善第一时相胰岛素分泌指数(IS1,11 mmol/l葡萄糖±多格列艾汀:3.9倍 vs 7.3倍,p=0.01;20 mmol/l葡萄糖±多格列艾汀:5.5倍 vs 9.0倍,p=0.13)。
临床怎么用
- 等基因iPSC来源胰岛平台可用于测试治疗婴幼儿KATP通道功能丧失所致高胰岛素血症的药物。
- 该平台可筛选改善成人杂合子携带者葡萄糖反应性胰岛素分泌的药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: An R1420H variation in sulfonylurea receptor 1 (SUR1), a subunit of the KATP channel, was previously identified in an Indigenous community in Arizona where a homozygous carrier (1420HH) had hyperinsulinaemic hypoglycaemia during infancy (HHI), suggestive of a KATP channel loss of function (LoF). Interestingly, heterozygous carriers of this variation (1420RH, occurring in 3% of the community), had a twofold increased risk of type 2 diabetes. We aimed to create an isogenic induced pluripotent stem cell (iPSC)-derived pancreatic islet (SC-islet)-based platform to test whether the R1420H variant results in KATP channel LoF, and to examine the distinct temporal effects of SUR1 1420HH and 1420RH KATP channel variations on insulin secretion from developing and mature SC-islets. METHODS: Using CRISPR-Cas9, isogenic iPSCs with all three genotypes (SUR1 1420RR, 1420RH and 1420HH) were generated from two different parental Indigenous American iPSC lines (IS1, isogenic cell lines derived from parental cell line 1; and IS2, isogenic cell lines derived from parental cell line 2). These isogenic cell lines were used to generate immature SC-islets (resembling fetal islets) and mature SC-islets (resembling adult islets), which were used to assess insulin secretion dynamics during different stages of development and identify differences in gene expression by single-cell RNA-seq. This study was consistent with the CONSIDER statement for research studies among Indigenous American communities. RESULTS: Immature SUR1 1420HH SC-islets secreted 3.4-fold (IS1, p<0.001) and 4.2-fold (IS2, p=0.001) more insulin under basal conditions than normal (SUR1 1420RR) SC-islets. Modest hyperinsulinaemia was also seen in immature SUR1 1420RH SC-islets (2.2-fold [IS1] and 2.3-fold [IS2]) but the results were not statistically significant. After maturation, the 1420HH SC-islets failed to achieve glucose responsiveness whereas the 1420RH SC-islets achieved biphasic insulin secretion but had significantly lower glucose responsiveness than normal SC-islets (AUC for insulin secretion [as a % of total insulin] under high glucose challenge: 1.04 vs 0.56 in normal vs 1420RH SC-islets, p<0.001). Diazoxide reduced hyperinsulinaemia in SUR1 1420RH and 1420HH immature SC-islets, while tolbutamide elicited a greatly diminished or undetectable insulin secretory response from mature SUR1 1420RH SC-islets (13.2-fold increase in insulin secretion) and 1420HH SC-islets (1.9-fold increase) compared with normal SC-islets (31.5-fold increase). Results were directionally comparable for both IS1 and IS2 SC-islets. SUR1 1420RH SC-islets also responded to the glucokinase activator dorzagliatin with improvement in first-phase insulin secretory response (first-phase stimulation index: 3.9-fold vs 7.3-fold, p=0.01 [IS1, 11 mmol/l glucose ± dorzagliatin]; 5.5-fold vs 9.0-fold, p=0.13 [IS1, 20 mmol/l glucose ± dorzagliatin]). Single-cell RNA-seq identified dysregulated genes in SUR1 1420RH SC-beta cells, including lower expression of glycolytic genes and upregulation of G6PC2, which could explain the lower insulin secretory response to glucose. CONCLUSIONS/INTERPRETATION: A SUR1 R1420H variant identified in an Indigenous American population causes hyperinsulinaemia in homozygous immature SC-islets during basal conditions and these SC-islets fail to achieve glucose responsiveness after maturation. In the heterozygous state, modest hyperinsulinaemia is observed in immature SC-islets, which after maturation have significantly lower glucose responsiveness. These results demonstrate that SUR1 R1420H is a KATP channel LoF variation and suggest that a lower insulin secretory response during adulthood is the cause of the higher type 2 diabetes risk in individuals heterozygous for this variation. We also show that the isogenic iPSC-based platform can be used to test therapeutic agents to treat HHI in infants homozygous for LoF KATP channels and screen for drugs that can improve glucose-responsive insulin secretion in adult heterozygous carriers. DATA AVAILABILITY: See the database of Genotypes and Phenotypes (dbGaP; dbgap.ncbi.nlm.nih.gov/home; accession no.: phs002490.v1.p1) for details concerning data requests. All source codes can be found in the GitHub repository under https://github.com/Koushik-Cheranda/SC-islet-scRNAseq-analysis-R-codes .
引用
- Nair AK, Barkho K, Cheranda KP, et al. Modelling the effects of human SUR1 R1420H variation on insulin secretory function using isogenic iPSC-derived pancreatic islets. Diabetologia. 2025. PMID: 41291239. doi:10.1007/s00125-025-06605-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。